南非高结核症状流行区当日启动HIV治疗的临床算法:SLATE II 个体随机临床试验
SLATE II 是在南非约翰内斯堡三家初级保健诊所开展的 1:1 个体随机实用试验,纳入 593 例成年 HIV 阳性非妊娠患者,评估修订版 SLATE II 算法(允许轻度结核症状者当日启动 ART)与常规护理相比的效果。结果显示干预组 7 天内启动率 91% 对 68%,28 天内启动且 8 个月保留率 74% 对 59%,病毒抑制与安全性未见明显受损,超过 85% 就诊者符合当日启动条件。
要点
- SLATE II 算法使 7 天内 ART 启动率提高 23 个百分点(91% 对 68%)。
- 8 个月时启动且保留复合终点干预组 74% 对对照组 59%。
- 有结核症状者中 72% 仍符合当日启动条件,未明显影响病毒抑制。
核心结论
- 超过 85% 的 HIV 检测或就诊患者(包括新诊断者)符合 SLATE II 算法当日启动条件。
- 该算法提高了 7 天内启动率,且未明显损害 8 个月保留率和病毒抑制。
研究设计与样本
- 非盲、1:1 个体随机实用试验,在南非约翰内斯堡三家初级保健诊所开展。
- 纳入 593 例成年 HIV 阳性非妊娠患者,中位年龄 35 岁(IQR 29-43),63% 为女性,中位 CD4 计数 293(IQR 133-487)。
- 干预组用症状筛查、病史、简要体检和准备度问卷区分可立即发药者与需进一步照护者,对照组接受常规护理,随访通过常规诊所记录回顾。
主要发现
- 干预组 7 天内启动率 91%,对照组 68%,风险差 23%(95%CI 17%-29%)。
- 干预组 28 天内启动率 94%,对照组 82%,风险差 12%(95%CI 7%-17%)。
- 8 个月时启动且保留复合终点干预组 74%(220/296),对照组 59%(175/297),风险差 15%(95%CI 7%-23%)。
- 有病毒载量结果者中,28 天内启动者病毒抑制率对照组 90%、干预组 92%。
- 启动后未报告 ART 相关不良事件;被动随访期间干预组 2 例、对照组 4 例死亡。
关键数值与推荐
- 140 例有结核症状的干预组患者中 72% 符合当日启动条件。
- 295 例(半数)研究患者有结核症状,但仅对照组 13 例(4%)和干预组 7 例(2%)检出结核病。
- 干预组 87% 与对照组 38% 的患者在入组当日启动 ART。
临床怎么用
- SLATE II 算法可广泛且立即供现有医务人员使用,用于筛选适合当日启动 ART 的患者。
- 轻度结核症状不再是当日启动的绝对障碍,可结合症状筛查与准备度评估进行分流。
局限性
- 地理外推性有限,排除了病情过重无法知情同意的患者。
- 对照组程序在研究期间有波动,研究人员对方案依从性高。
- 数据限制可能导致失访被高估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many countries encourage same-day initiation of antiretroviral therapy (ART), but evidence on eligibility for same-day initiation, how best to implement it, and its impact on outcomes remains scarce. Building on the Simplified Algorithm for Treatment Eligibility (SLATE) I trial, in which nearly half of participants were ineligible for same-day initiation mainly because of TB symptoms, the study evaluated the revised SLATE II algorithm, which allowed same-day initiation for patients with mild TB symptoms and other less serious reasons for delay. METHODS AND FINDINGS: SLATE II was a nonblinded, 1:1 individually randomized pragmatic trial at three primary healthcare clinics in Johannesburg, South Africa. It randomized adult patients presenting for an HIV test or any HIV care but not yet on ART. Intervention arm patients were assessed with a symptom screen, medical history, brief physical examination, and readiness questionnaire to distinguish between patients eligible for immediate ART dispensing and those requiring further care before initiation. Standard arm patients received usual care. Follow-up was by review of routine clinic records. Primary outcomes were (1) ART initiation in ≤7 days and (2) ART initiation in ≤28 days and retention in care at 8 months (composite outcome). From 14 March to 18 September 2018, 593 adult HIV+, nonpregnant patients were enrolled (median interquartile range [IQR] age 35 [29-43]; 63% (n = 373) female; median CD4 count 293 [133-487]). Half of study patients (n = 295) presented with TB symptoms, whereas only 13 (4%) standard arm and 7 (2%) intervention arm patients tested positive for TB disease. Among 140 intervention arm patients with TB symptoms, 72% were eligible for same-day initiation. Initiation was higher in the intervention (n = 296) versus standard arm (n = 297) by 7 days (91% versus 68%; risk difference [RD] 23% [95% confidence interval (CI) 17%-29%]) and 28 days (94% versus 82%; RD 12% [7%-17%]) after enrollment. In total, 87% of intervention and 38% of standard arm patients initiated on the same day. By 8 months after study enrollment, 74% (220/296) of intervention and 59% (175/297) of standard arm patients had both initiated ART in ≤28 days and been retained in care (RD 15% [7%-23%]). Among the 41% of participants with viral load results available, suppression was 90% in the standard arm and 92% in the intervention arm among patients initiated in ≤28 days. No ART-associated adverse events were reported after initiation; two intervention and four standard arm patients were reported to have died during passive follow-up. Limitations of the study included limited geographic generalizability, exclusion of patients too sick to consent, fluctuations in procedures in the standard arm over the course of the study, high fidelity to the trial protocol by study staff, and the possibility of overestimating loss to follow-up due to data constraints. CONCLUSIONS: More than 85% of patients presenting for HIV testing or care, including those newly diagnosed, were eligible and ready for same-day initiation under the SLATE II algorithm. The algorithm increased initiation within 7 days without appearing to compromise retention and viral suppression at 8 months, offering a practical and acceptable approach that can be widely and immediately utilized by existing providers. TRIAL REGISTRATION: Clinicaltrials.gov NCT03315013, registered 19 October 2017. First participant enrolled 14 March 2018.
引用
- Maskew M, Brennan AT, Fox MP, et al. A clinical algorithm for same-day HIV treatment initiation in settings with high TB symptom prevalence in South Africa: The SLATE II individually randomized clinical trial. PLoS Med. 2020. PMID: 32853271. doi:10.1371/journal.pmed.1003226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。